Bumble Inc vs Eli Lilly And Co — how do they compare? Bumble Inc trades at $2.63 (market cap $366.87M), while Eli Lilly And Co trades at $1,215 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 2943.8× Bumble Inc's market cap, and Eli Lilly And Co pays a 0.57% dividend while Bumble Inc pays none. Which is the better fit depends on your goals.
| BMBL | LLY | |
|---|---|---|
Market Cap | $366.87M | $1.08T |
Sector | Technology | Health |
52-Week High | $7.17 | $1.24K |
52-Week Low | $2.70 | $639.43 |
Enterprise Value | $672.73M | $1.13T |
Dividend Yield | — | 0.57% |
Signals from Pluang's Aura AI — not financial advice
Bumble (BMBL) trades at $2.62, down 4.03% on the day, reflecting ongoing investor concerns. The stock is in a bearish technical trend with negative earnings and declining revenue. Recent strategic shifts, including removing the women-first messaging rule and exploring a sale, aim to revive growth amid falling paying users. Valuation ratios like P/S of 0.38 and P/B of 0.71 appear low, but profitability remains weak with a net income margin of -57.96%.
The outlook is cautious; while cost controls and product changes could stabilize the business, persistent losses and competitive pressures pose significant risks. Analyst consensus is mixed with a $3.62 price target, but high institutional selling and bearish sentiment suggest limited near-term upside. Investors should weigh potential turnaround against execution risks and market skepticism.
Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.
LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.
Trailing returns across standard periods
Latest headlines on both assets
Bumble Inc is engaged in offering online dating services. The company operates two apps, Bumble and Badoo, where users come on a monthly basis to discover new people and connect with each other.
Read more on BMBL →Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →